SEC Tracker
Get the app

Mycotopia Therapies AIBT

Mycotopia Therapies FY 2023: net loss $1.2M

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Mycotopia Therapies reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$1.2MAgainst −$2.6M in FY 202210-K income statement, on EDGAR
  2. Cash and cash equivalents$279K−28% from $386K in FY 202210-K balance sheet, on EDGAR
  3. Cash from operations−$107KAgainst −$657K in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Mycotopia Therapies files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2833 and related industry codes: the same peer list as the financial tables.

  1. Agentix AGTX public float $1M, Sep 30, 2025
  2. Galera Therapeutics GRTX public float $2M, Jun 30, 2025
  3. ProtoKinetix PKTX public float $2M, Jun 30, 2026
  4. Evofem Biosciences EVFM public float $1M, Jun 30, 2025
  5. Regen BioPharma RGBP public float $1M, Mar 31, 2025, over 18 months old